Immunocore (NASDAQ:IMCR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.12), Briefing.com reports. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The business had revenue of $70.30 million for the quarter, compared to analyst estimates of $70.72 million. During the same quarter last year, the firm posted ($0.35) EPS. The company's revenue was up 27.6% compared to the same quarter last year.
Immunocore Trading Down 2.4 %
IMCR stock traded down $1.47 during midday trading on Thursday, reaching $59.85. The stock had a trading volume of 540,493 shares, compared to its average volume of 475,137. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. Immunocore has a twelve month low of $42.21 and a twelve month high of $76.98. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -51.46 and a beta of 0.92. The business has a fifty day simple moving average of $60.76 and a two-hundred day simple moving average of $61.33.
Wall Street Analysts Forecast Growth
IMCR has been the subject of several recent analyst reports. Oppenheimer reiterated an "outperform" rating and issued a $87.00 price objective (up from $85.00) on shares of Immunocore in a report on Thursday, February 29th. SVB Leerink began coverage on Immunocore in a report on Monday, April 29th. They issued an "outperform" rating and a $74.00 price objective for the company. Canaccord Genuity Group lifted their target price on Immunocore from $63.00 to $67.00 and gave the stock a "hold" rating in a report on Thursday. Leerink Partnrs reissued an "outperform" rating on shares of Immunocore in a report on Monday, April 29th. Finally, JPMorgan Chase & Co. increased their target price on shares of Immunocore from $60.00 to $70.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, Immunocore has a consensus rating of "Moderate Buy" and a consensus target price of $82.00.
Check Out Our Latest Stock Analysis on Immunocore
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
